Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Is HER2 overexpression sufficient for optimal response to Pertuzumab?

Sendur MA, Aksoy S, Yaman S, Özdemir NY, Zengin N.

Med Oncol. 2012 Dec;29(4):2565-6. doi: 10.1007/s12032-012-0183-2. Epub 2012 Feb 16. No abstract available.

PMID:
22351251
2.

HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.

Ellis MJ.

J Natl Cancer Inst. 2014 Aug 19;106(8). pii: dju212. doi: 10.1093/jnci/dju212. Print 2014 Aug. No abstract available.

PMID:
25139535
3.

Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.

Danese MD, Masaquel A, Santos E, Brammer M, Lee A, Lalla D.

Value Health. 2015 Sep;18(6):876-83. doi: 10.1016/j.jval.2015.06.003. Epub 2015 Aug 13.

4.

Pertuzumab: optimizing HER2 blockade.

Metzger-Filho O, Winer EP, Krop I.

Clin Cancer Res. 2013 Oct 15;19(20):5552-6. doi: 10.1158/1078-0432.CCR-13-0518. Epub 2013 Aug 13. Review.

5.

Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.

Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F.

Expert Opin Biol Ther. 2017 Mar;17(3):365-374. doi: 10.1080/14712598.2017.1282944. Epub 2017 Jan 30. Review.

PMID:
28092723
6.

Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.

Ajgal Z, de Percin S, Diéras V, Pierga JY, Campana F, Fourquet A, Kirova YM.

Cancer Radiother. 2017 Apr;21(2):114-118. doi: 10.1016/j.canrad.2016.10.002. Epub 2017 Mar 24.

PMID:
28347625
7.

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.

Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4.

8.

Pertuzumab for the treatment of metastatic breast cancer.

Langdon SP, Cameron DA.

Expert Rev Anticancer Ther. 2013 Aug;13(8):907-18. doi: 10.1586/14737140.2013.814419. Review.

PMID:
23984893
9.

[A case of HER2-positive breast cancer for which preoperative chemotherapy with pertuzumab resulted in a pathological complete response].

Abe H, Yamazaki K, Yoneda K, Ogawa M, Kawasaki M, Yoneda G, Yoshimura M, Kameyama M.

Gan To Kagaku Ryoho. 2015 Apr;42(4):485-8. Japanese.

PMID:
25963698
10.

Pertuzumab protects the achilles' heel of trastuzumab--emtansine.

Gwin WR, Spector NL.

Clin Cancer Res. 2014 Jan 15;20(2):278-80. doi: 10.1158/1078-0432.CCR-13-2626. Epub 2013 Nov 15.

11.

POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.

Goel S, Winer EP.

Oncology (Williston Park). 2015 Nov;29(11):797-8, 802. No abstract available.

12.

Pertuzumab: increasing the options.

Nunes R, Swain SM.

Oncology (Williston Park). 2014 Mar;28(3):199, 204, 210. No abstract available.

13.

Treatment combinations for HER2-positive breast cancer.

Pegram M.

Oncology (Williston Park). 2013 Apr;27(4):258, 260. No abstract available.

PMID:
23781688
14.

What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?

Von Minckwitz G, Loibl S, Untch M.

Oncology (Williston Park). 2012 Jan;26(1):20-6. Review.

15.

[Pertuzumab and solid tumors: perspectives].

Barthélémy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP.

Bull Cancer. 2014 Dec;101(12):1114-21. doi: 10.1684/bdc.2014.2026. French.

PMID:
25532690
16.

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

Baselga J, Cortés J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM.

J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20.

PMID:
25332247
17.

Neoadjuvant pertuzumab: the exception that proves the rule?

Burstein HJ.

Oncology (Williston Park). 2014 Mar;28(3):197-9. No abstract available.

18.

[Pertuzumab+trastuzumab+DTX therapy].

Maejima A, Tamura K.

Nihon Rinsho. 2015 Feb;73 Suppl 2:553-7. Japanese. No abstract available.

PMID:
25831821
19.

FDA approves pertuzumab for breast cancer.

Traynor K.

Am J Health Syst Pharm. 2012 Jul 15;69(14):1178. doi: 10.2146/news120049. No abstract available.

PMID:
22761063
20.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722

Supplemental Content

Support Center